Recommend a Friend

and earn £100 to share

We're committed to giving our clients the best deal and the best service possible. That’s why 98% of our clients would recommend us to others.

Recommend a friend to Chase Templeton and when they take out a Private Medical Insurance policy through us, we'll give you both £50 to say 'thank you', you can’t say fairer than that.

Plus, with no limit on the number of friends you recommend your Private Medical Insurance could pay for itself!

There are so many reasons for your friend to choose us for their private healthcare needs, and now with £100 to share when you recommend them to us, there’s never been a better time to spread the word.

  • We don't charge any upfront or hidden fees
  • We are wholly independent of any insurer and search the whole market to find the best deal
  • We're known for our straight talking, clear and helpful approach. It's a reputation we're proud of
  • We also don't believe in confusing automated telephone systems, so when you call us you'll speak to a real person - not a machine.

 

It's easy to recommend a friend:

1

Ask your friend to call us on 0800 018 3633

2

Your friend must mention your name so we can give you your reward too

3

Once your friend takes out a Private Medical Insurance policy we'll credit both your bank accounts with £50

Terms and conditions:

1. Recommend a Friend is only valid when your friend takes out a Private Medical Insurance policy
2. Friends or family who live at your address are not included in this promotion
3. £50 will be paid to you and your friend within 12 weeks of the policy being sold
4. There is no limit to the number of friends you recommend
5. This offer may be withdrawn at any time.

Why choose us?

  • Our services are free
  • 100% impartial and honest advice
  • We search the whole market
  • Real people, not machines

Latest News

14/02/2012
Two more cancer drugs have been provisionally banned for NHS after it was decided they were too expensive for the potential results.
02/02/2012
A drug that can extend the life of men with advanced prostate cancer by more than three months has provisionally been rejected for NHS use.
All news articles